The litigation, brought on behalf of investors by Bleichmar Fonti & Auld LLP, centers on the company’s handpiece sales for its robotic surgery systems. While Procept previously maintained that handpiece shipments aligned consistently with procedure volume, the complaint alleges these figures were bolstered by an extensive discount program. This strategy reportedly led to a cumulative excess field inventory of more than 10,000 units by early 2026.
In section Releases
Procept BioRobotics Faces Securities Fraud Lawsuit Over Sales Practices
A securities fraud class action lawsuit has been filed against PROCEPT BioRobotics Corporation in the U.S. District Court for the Northern District of California, following allegations that the company artificially inflated its financial performance through aggressive discount programs that encouraged bulk orders exceeding actual surgical demand.
Investors suffered significant losses following disclosures regarding these inventory imbalances. The most severe impact occurred after the company’s February 2026 announcement, which revealed a 30% contraction in U.S. handpiece unit sales, triggering an 18% drop in stock price over two trading days. Previous quarterly reports in August and November 2025 similarly prompted double-digit declines as the company adjusted its sales guidance and admitted to customer overstocking. Shareholders seeking to serve as lead plaintiff in the case, captioned Operating Engineers Construction Industry and Miscellaneous Pension Fund v. PROCEPT BioRobotics Corporation, must file by September 22, 2026.
Comments (0)
No comments yet. Be the first!